The RAC 3-Pillar Trifecta, page-184

Applications outside oncology are speculative only until if/when bisantrene is proven to cross the blood-brain barrier.

After that is proven, they would be no more speculative than an oncology FTO indication. You've already provided a long list of CNS indications where FTO is known to play a role.

The only new information is that until June 2020 it wasn't known to anyone other than City of Hope that bisantrene is a super-potent FTO inhibitor.

Please feel free to add in another couple of USD $10 billions, with an appropriate associated probability. Sheba results are partial response in 2/2 CNS metasteses, suggesting that the blood brain barrier was crossed.